SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript

Core Insights - SOPHiA GENETICS S.A. reported a strong Q3 performance with a 23% year-over-year revenue growth, driven by new customer signings and expansion within existing accounts [4][27][40] - The company raised its 2025 revenue guidance to a range of $75 million to $77 million, reflecting confidence in continued growth momentum [3][36] Customer Growth and Expansion - In Q3, SOPHiA signed 31 new customers, bringing the total for 2025 to 94, surpassing the previous year's total of 92 [3][17] - The company successfully expanded its offerings at existing institutions, including major deals with Gustave Roussy and New South Wales Pathology [2][5] Market Performance - U.S. revenue grew by 30% year-over-year, contributing significantly to overall growth [1][15] - EMEA region saw a 24% revenue growth, with notable contributions from the UK and Belgium, which grew by 120% and 70% respectively [14][15] Product Development and Innovation - The company highlighted the success of its liquid biopsy application, MSK Access, which is gaining traction among customers [5][7] - SOPHiA introduced a new technology called SOPHiA DDM Digital Twins, aimed at enhancing treatment decision-making for oncologists [9][10] Financial Performance - Total revenue for Q3 was $19.5 million, compared to $15.9 million in the same quarter last year, with gross profit increasing to $12.9 million [27][29] - Adjusted gross margin remained strong at 73.1%, despite a significant increase in data processed by the platform [11][29] Strategic Partnerships - The partnership with AstraZeneca is expected to enhance market access for liquid biopsy testing and contribute to drug development [7][21] - Collaborations with Myriad Genetics and ADAM Innovations are aimed at developing regulated companion diagnostics in the U.S. and Japan [7][21][63] Future Outlook - The company anticipates continued growth in 2026, driven by strong customer demand and the successful implementation of new applications [36][70] - SOPHiA is focused on optimizing costs while expanding its customer base and product offerings [12][38]